Skip to main content
All blogsResearch

Peptides for Women: A Goal-by-Goal Guide

Most pages about peptides for women sort them by decade. This one sorts them by what you actually want: body composition, skin, sleep, desire, energy and recovery, immune support. For each goal it names the peptides PeRx prescribes, what the evidence in women supports, and what none of them will do.

PeRx PeptidesReviewed by Dr. Cory Mellon, MD17 min readPublished
Organized by goal rather than age: body composition, skin and hair, sleep, desire, energy and immune support, with the screen-outs stated up front.
Organized by goal rather than age: body composition, skin and hair, sleep, desire, energy and immune support, with the screen-outs stated up front.

Key Takeaways

  • Women are not a smaller version of the male patient: premenopausal women release more growth hormone per pulse than men, their tendons respond to loading differently, and sleep breaks up at predictable points in the reproductive timeline. Matching a peptide to a goal starts there.
  • Body composition has two lanes: compounded semaglutide with B12 ($249) or compounded tirzepatide with B12 ($399), which are not the FDA-approved brands Ozempic, Wegovy, Mounjaro or Zepbound, and growth hormone secretagogues such as sermorelin, CJC-1295/ipamorelin and tesamorelin, which raise your own GH pulses and change composition slowly.
  • GHK-Cu has the strongest biological rationale for skin and the thinnest injectable human data; the published human results are topical, and hair-growth claims belong to serum products PeRx does not sell.
  • PT-141 is the same molecule as Vyleesi, FDA-approved in 2019 for premenopausal women with acquired, generalized hypoactive sexual desire disorder. Compounded PT-141 has not been through FDA review and is not prescribed as a treatment for that diagnosis.
  • Pregnancy, breastfeeding, trying to conceive, and active cancer rule out every peptide here. GH secretagogues add a hormone-sensitive cancer history, PT-141 adds uncontrolled blood pressure, and the compounded GLP-1s add a personal or family history of medullary thyroid carcinoma. No peptide on this page raises estrogen or progesterone or treats a menopausal symptom.

Quick Facts

Sorted by

Goal, not age. Six goals, each mapped to catalog peptides

Body composition

Compounded GLP-1s ($249 / $399 per 28 days) or GH secretagogues ($229 to $299)

Skin and hair

GHK-Cu ($229), GHK-Cu/Epitalon ($299), KLOW ($349)

Sleep

DSIP ($229), Pinealon/PE-22-28/Selank blend ($299)

Desire

PT-141 ($229), the compounded form of bremelanotide

Energy and recovery

NAD+ ($229), BPC-157 ($229), BPC/TB-500 ($299), Glutathione ($199)

Immune support

Thymosin Alpha-1 ($229)

Screened out

Pregnancy, breastfeeding, trying to conceive, active cancer

Last reviewed

September 28, 2026

Why This Guide Is Sorted by Goal

Type peptides for women into a search box and the results sort themselves by decade. Women in their 20s. Women over 40. Women over 50. The framing is convenient for a headline and wrong for a decision. A 34-year-old runner with an Achilles that will not settle and a 52-year-old who cannot stay asleep past 3 a.m. are not looking for the same thing. Age changes the odds that a given goal is on your list. It does not change which peptide addresses the goal.

So this guide sorts by the goal. Six of them account for nearly every consult a woman books with a peptide provider: body composition and weight, skin and hair, sleep, desire, energy and recovery, and immune support. Each section names the peptides in the PeRx catalog that touch that goal, says what the human evidence supports, with particular attention to studies that enrolled women, and says what the peptide will not do. The age-specific questions have their own pages: best peptides for women over 40 ranks the options for that decade, peptides for perimenopause symptoms works symptom by symptom, peptides and menopause grades the evidence by stage, and peptides after 60 covers dosing. This page is the map they hang from.

Three differences in female physiology matter before any peptide is chosen. Growth hormone first: in a 24-hour blood-sampling study, young women released more GH than young men, the gap tracked estradiol, and output fell with age in both sexes. A later analysis traced the difference to women releasing more GH per secretory burst. A secretagogue that amplifies those bursts lands on a different baseline in a woman, and a very different one once menopause removes the estrogen support. Connective tissue second: a review of sex differences in tendon physiology found that women's tendons answer loading with a smaller rise in collagen synthesis than men's, with estrogen implicated, which is one reason recovery peptides come up so often in women's consults. Sleep third: in the SWAN cohort, difficulty sleeping became more common with each stage of the menopausal transition.

Ho KY, Evans WS, Blizzard RM, et al. "Effects of sex and age on the 24-hour profile of growth hormone secretion in man: importance of endogenous estradiol concentrations." J Clin Endocrinol Metab, 1987. PMID 3782436. View study

van den Berg G, Veldhuis JD, Frölich M, Roelfsema F. "An amplitude-specific divergence in the pulsatile mode of growth hormone (GH) secretion underlies the gender difference in mean GH concentrations in men and premenopausal women." J Clin Endocrinol Metab, 1996. PMID 8675561. View study

Hansen M, Kjaer M. "Influence of sex and estrogen on musculotendinous protein turnover at rest and after exercise." Exerc Sport Sci Rev, 2014. PMID 25062001. View study

Kravitz HM, Zhao X, Bromberger JT, et al. "Sleep disturbance during the menopausal transition in a multi-ethnic community sample of women." Sleep, 2008. PMID 18652093. View study

The Map: Goal to Peptide

Here is the whole page in one table. Read the last column first: it is the one the ranked lists leave out.

Body composition and weight

Peptides in the PeRx catalog
Compounded semaglutide + B12, compounded tirzepatide + B12; sermorelin, CJC-1295/ipamorelin, tesamorelin; MOTS-c
What the evidence supports
The trial record belongs to the approved GLP-1 brands, not the compounded copies. Secretagogues raise GH and IGF-1; composition changes are slow. MOTS-c human data is observational.
What it will not do
Replace training, protein, or sleep. Spot-reduce.

Skin and hair

Peptides in the PeRx catalog
GHK-Cu; GHK-Cu/Epitalon; KLOW
What the evidence supports
Coherent biology, human data mostly topical. Postmenopausal collagen loss is well documented.
What it will not do
Regrow hair. Stand in for estrogen in skin.

Sleep

Peptides in the PeRx catalog
DSIP; Pinealon/PE-22-28/Selank blend
What the evidence supports
Small, old, mixed human studies. Patient report drives use.
What it will not do
Treat insomnia. Stop night sweats.

Desire

Peptides in the PeRx catalog
PT-141
What the evidence supports
High for the approved drug, Vyleesi, in premenopausal women; the compounded product is unreviewed.
What it will not do
Raise testosterone. Treat vaginal dryness. Fix a relationship.

Energy and recovery

Peptides in the PeRx catalog
NAD+; BPC-157; BPC/TB-500; Glutathione
What the evidence supports
One small trial of an oral NAD precursor in postmenopausal women; BPC-157 is animal data; glutathione is not an energy drug.
What it will not do
Fix fatigue with an unexamined cause: thyroid, iron, sleep apnea.

Immune support

Peptides in the PeRx catalog
Thymosin Alpha-1
What the evidence supports
Approved abroad for specific infections; US use is off-label.
What it will not do
Prevent illness. Treat autoimmune disease.

Goal: Body Composition and Weight

The reason this goal tops the list after 40 is not willpower. In a four-year longitudinal study of women crossing the menopausal transition, fat mass rose while 24-hour energy expenditure and fat oxidation fell, and the increase in visceral fat was concentrated in the women who became postmenopausal during the study. Younger women arrive at the same goal for different reasons: a plateau, a postpartum shift, a body that stopped answering a program that used to work. The two lanes below are not interchangeable.

Lovejoy JC, Champagne CM, de Jonge L, Xie H, Smith SR. "Increased visceral fat and decreased energy expenditure during the menopausal transition." Int J Obes (Lond), 2008. PMID 18332882. View study

Lane one: the compounded GLP-1s

PeRx prescribes compounded semaglutide with vitamin B12 ($249 per 28 days) and compounded tirzepatide with vitamin B12 ($399 per 28 days), prepared per prescription by a 503A pharmacy. They are not Ozempic, Wegovy, Mounjaro, or Zepbound. Those are FDA-approved products from Novo Nordisk and Eli Lilly, and the large trials you have read about were run on them. The compounded preparations have not been through FDA review, and nothing here claims that a compounded vial performs the way an approved product did in its trials. The B12 is there because the pharmacy formulates it that way, not because it has been shown to reduce side effects or improve results.

These two are the only subscriptions in the PeRx catalog: one vial every 28 days with a provider review each cycle, and you can cancel. Sublingual versions of both are listed as coming soon and are not yet available. Semaglutide vs tirzepatide walks through the differences, what compounded semaglutide is explains the pharmacy side, and gray-market vs compounded GLP-1s explains why the source matters more than the molecule.

Two second-order effects come up in women more than in men, and each has a page: muscle loss on GLP-1s for lean mass during rapid weight loss, Ozempic face and hair loss on GLP-1s for what can follow a fast drop. A woman on hormone therapy should read semaglutide and menopause first, and a woman on the pill should read the screening section below.

Lane two: growth hormone secretagogues

Sermorelin ($229), CJC-1295/ipamorelin ($299), and tesamorelin ($229) do not add growth hormone. They ask the pituitary to release more of your own, in pulses, with the feedback loops intact. A 2018 review concluded that these agents reliably raise GH and IGF-1 in adults with a favorable short-term safety profile and no long-term outcome data. The change they produce is a slow recomposition over months, more lean tissue kept and somewhat less fat, not a number on the scale. Tesamorelin has an FDA approval for HIV-associated abdominal fat, not for the general population.

Two things matter for women here. Oral estrogen lowers IGF-1 through the liver while transdermal estrogen does not, which changes how a baseline lab reads, so the route of any hormone therapy belongs on the intake form. And a hormone-sensitive cancer history is a screen-out, because GH and IGF-1 signaling is growth signaling. Sermorelin vs ipamorelin vs tesamorelin compares the three, and the CJC-1295/ipamorelin guide covers the combination most women ask about.

Sigalos JT, Pastuszak AW. "The Safety and Efficacy of Growth Hormone Secretagogues." Sex Med Rev, 2018. PMID 28400207. View study

MOTS-c, for the woman who trains

MOTS-c ($229) is a mitochondrial-derived peptide. In a 2021 study, its levels rose in muscle and blood after exercise in humans, and late-life treatment in mice improved physical capacity. The human part of that work is observational; nobody has run a controlled trial of injected MOTS-c for body composition in women. It is prescribed for the woman whose training has stopped producing returns, on the strength of the biology and of patient report, and the MOTS-c guide is honest about that gap.

Reynolds JC, Lai RW, Woodhead JST, et al. "MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis." Nat Commun, 2021. PMID 33473109. View study

Goal: Skin and Hair

Skin is where female physiology shows its hand most visibly. Brincat and colleagues measured skin collagen content and thickness in postmenopausal women and found both fell with years since menopause, and a 2013 review of estrogens and aging skin describes what follows: dryness, thinning, fine wrinkling, slower wound healing. Peptides do not put the estrogen back. What GHK-Cu offers is a repair signal that works regardless.

Brincat M, Kabalan S, Studd JW, Moniz CF, de Trafford J, Montgomery J. "A study of the decrease of skin collagen content, skin thickness, and bone mass in the postmenopausal woman." Obstet Gynecol, 1987. PMID 3120067. View study

Thornton MJ. "Estrogens and aging skin." Dermatoendocrinol, 2013. PMID 24194966. View study

GHK-Cu ($229) is a copper-binding tripeptide that declines in plasma with age. Pickart's 2018 analysis of gene-expression data catalogues its effects on collagen and elastin synthesis, on the enzymes that remodel skin, and on inflammatory signaling. The catch is the route. The human evidence is topical: small studies of creams and serums showing thicker, firmer skin. Injected GHK-Cu has coherent biology and thin human data, and the GHK-Cu guide says so plainly. After a fast weight loss, GHK-Cu for skin after GLP-1 weight loss takes on the question of loose skin.

Pickart L, Margolina A. "Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data." Int J Mol Sci, 2018. PMID 29986520. View study

Two combinations extend it. GHK-Cu/Epitalon ($299) pairs the skin peptide with a telomerase-associated peptide from the Russian bioregulator literature. KLOW ($349) puts GHK-Cu alongside BPC-157, KPV and TB-500 for skin and tissue repair together, and it is the closest thing in the catalog to the GLOW stack people search for; GLOW itself is not a PeRx product, and the GLOW page explains where it routes. Peptides for glowing skin is the practical comparison.

Hair deserves a plain sentence. The copper peptides for hair growth you see advertised are topical serums, and the studies behind them are topical. There is no injectable human data showing GHK-Cu regrows hair, PeRx sells no hair serum, and a woman losing hair should have ferritin, thyroid function, and a medication review before any peptide conversation.

Goal: Sleep

Sleep breaks in women at predictable points: the postpartum year, the late luteal phase for some, the menopausal transition for most. What peptides can offer here is limited and should be described that way.

DSIP ($229), delta sleep-inducing peptide, was isolated in the 1970s and studied in small human trials through the 1990s. A 2006 review called it a still unresolved riddle: some studies found better sleep measures, others found nothing, and no receptor was ever confirmed. It is not a sedative and not a treatment for insomnia; women who use it describe longer stretches of unbroken sleep, and that report, not a trial, drives its use. The DSIP guide, DSIP vs melatonin, and best peptides for sleep go deeper.

Kovalzon VM, Strekalova TV. "Delta sleep-inducing peptide (DSIP): a still unresolved riddle." J Neurochem, 2006. PMID 16539679. View study

The Pinealon/PE-22-28/Selank blend ($299) is the option for the woman whose sleep problem is a mind that will not stop. Selank is an anxiolytic peptide, PE-22-28 is a research compound derived from spadin, and Pinealon is a short synthetic peptide from the same bioregulator tradition as Epitalon; none of the three is a sedative, and Pinealon is not a melatonin or pineal peptide despite the name. What Pinealon is and the blend guide cover the evidence, which is small. None of these touch night sweats. If hot flashes are what wakes you, that conversation belongs with a clinician who prescribes hormone therapy, and PeRx does not.

Goal: Desire

This is the one goal with an FDA-approved peptide behind it, and the approval has edges. Bremelanotide, sold as Vyleesi, was approved by the FDA on June 21, 2019 for premenopausal women with acquired, generalized hypoactive sexual desire disorder. The two phase 3 trials behind it enrolled premenopausal women, dosed 1.75 mg under the skin on demand, and found modest but statistically significant improvements in desire and in distress about low desire versus placebo, with nausea the most common side effect. The dose had been selected in an earlier dose-finding trial in the same population.

Kingsberg SA, Clayton AH, Portman D, et al. "Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials." Obstet Gynecol, 2019. PMID 31599840. View study

Clayton AH, Althof SE, Kingsberg S, et al. "Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial." Womens Health (Lond), 2016. PMID 27181790. View study

PT-141 ($229) at PeRx is the same molecule, bremelanotide, prepared per prescription by a 503A pharmacy. It has not been through FDA review, it is not Vyleesi, and it is not prescribed as a treatment for hypoactive sexual desire disorder or any other diagnosis. It is prescribed for on-demand use, about 45 minutes before activity, and it works on melanocortin receptors in the brain rather than on hormones or blood flow. It does not raise testosterone or estrogen and does nothing for vaginal dryness. Expect flushing, possible nausea, and a temporary rise in blood pressure after each dose, which is why uncontrolled hypertension is a screen-out. PT-141 for women, PT-141 side effects, and how to use PT-141 cover the practical side. Postmenopausal women are outside the approved population; a prescriber who considers it for them is reasoning from mechanism, not trial data.

Goal: Energy and Recovery

Fatigue is the vaguest complaint in medicine and the one most often blamed on the wrong thing. Before any peptide, a woman with low energy should have thyroid function, ferritin, a B12 level, and a screen for sleep apnea: each is common in women, treatable, and not something a peptide fixes.

NAD+ ($229) is the coenzyme every cell uses to move energy, and its levels fall with age. The most relevant trial in women is small and indirect: 25 postmenopausal women with prediabetes took an oral NAD precursor, nicotinamide mononucleotide, for 10 weeks, and muscle insulin sensitivity improved while most other metabolic measures did not change. That trial did not test injected NAD+, which has no comparable controlled data. NAD injections and the NAD+ guide explain the difference between IV drips, injections, and precursors.

Yoshino M, Yoshino J, Kayser BD, et al. "Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women." Science, 2021. PMID 33888596. View study

BPC-157 ($229) is the recovery peptide women ask about most, usually for a tendon, a ligament, or a gut that will not settle. The evidence is almost entirely animal: a 2018 review summarizes the rat data on tendon, ligament, muscle, and gastrointestinal healing, and there is no controlled human trial. It comes up so often in women because of the tendon physiology described at the top of this page. BPC/TB-500 ($299) adds thymosin beta-4 for broader systemic recovery. Neither is a substitute for rehab, and the BPC-157 guide is candid about what the rat studies do and do not tell you. Peptides for joint pain goes joint by joint.

Sikiric P, Seiwerth S, Rucman R, et al. "Novel Cytoprotective Mediator, Stable Gastric Pentadecapeptide BPC 157. Vascular Recruitment and Gastrointestinal Tract Healing." Curr Pharm Des, 2018. PMID 29879879. View study

Glutathione ($199) belongs here only with a caveat. It is the main intracellular antioxidant, prescribed at PeRx on a detox and recovery rationale, and it is not an energy drug. PeRx does not prescribe it for the skin-lightening claims made in other countries, and the glutathione guide explains what it is for.

Goal: Immune Support

Thymosin Alpha-1 ($229) is a thymic peptide that modulates T-cell function. A 2020 review describes its approval in a number of countries for chronic hepatitis B and as a vaccine adjuvant, with a long safety record in those uses. In the United States it is not an approved drug, and PeRx prescribes it off-label for immune support, not to prevent or treat any infection. Autoimmune disease is far more common in women than in men, and a peptide that stimulates immune function is a question for the rheumatologist first. Peptides for autoimmune patients and the Thymosin Alpha-1 guide cover that conversation.

Dominari A, Hathaway Iii D, Pandav K, et al. "Thymosin alpha 1: A comprehensive review of the literature." World J Virol, 2020. PMID 33362999. View study

Who Is Screened Out

Every PeRx prescription starts with an intake that a licensed provider reviews, and for women the screen has a few extra lines.

Across the board: pregnancy, breastfeeding, actively trying to conceive, and active cancer. Peptides should be stopped before conception attempts, not after a positive test.

Growth hormone secretagogues: a history of hormone-sensitive cancer, including breast cancer, and poorly controlled diabetes, because GH nudges glucose upward.

PT-141: uncontrolled high blood pressure or cardiovascular disease, because of the transient pressure rise after each dose.

Compounded GLP-1s: a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2, a history of pancreatitis, and an active eating disorder. One line specific to women: the labeling for the approved tirzepatide products advises a backup method of contraception for four weeks after starting and after each dose increase, because absorption of oral contraceptives can drop in that window.

What to bring: every hormone you take and its route, testosterone if you use it, thyroid medication, and recent labs. What providers review before prescribing peptides and lab work before starting peptides list the rest.

How It Works at PeRx

The process is the same for every goal: an online intake reviewed by a licensed provider and, if appropriate, a prescription filled by a US 503A pharmacy. Vials ship fully reconstituted and ready to use, overnight in cold packaging. Peptides are per-prescription with no auto-renewal; the two compounded GLP-1s are the only subscriptions. Compounded peptides are cash-pay, though HSA and FSA funds usually apply. Their regulatory status has been in motion through 2026 and is not settled; where to buy peptides legally explains what a legitimate prescription looks like and why anything sold for research is a different product.

Peptides for Women: Common Questions

Some women, for some goals, after a screen. The question only has an answer once the goal is named: a woman with a tendon that will not heal and a woman whose sleep fell apart at 48 are asking different questions. Pregnancy, breastfeeding, trying to conceive, and active cancer rule peptides out regardless of goal.

There is no single best peptide for women, and any page that names one is selling it. By goal: compounded GLP-1s or GH secretagogues for body composition, GHK-Cu for skin, DSIP for sleep, PT-141 for desire, NAD+ or BPC-157 for energy and recovery, Thymosin Alpha-1 for immune support. The evidence ranges from strong for the approved drugs to thin for the older research peptides.

Injection-site reactions are common to all of them. GH secretagogues can cause water retention, tingling in the hands, and a small upward drift in blood sugar. PT-141 causes nausea in a large share of users and a temporary rise in blood pressure. The compounded GLP-1s bring nausea, constipation, and lean mass loss if protein and training are neglected. Across the board: no long-term outcome data, cash-pay pricing, and an unsettled regulatory status.

None of the peptides here raise estrogen, progesterone, or testosterone. GH secretagogues raise growth hormone and IGF-1, which are hormones, but not the reproductive ones. Cycle changes are not a commonly reported effect of any peptide on this page. If your cycle changes after you start one, tell your provider, and remember that rapid weight loss on a GLP-1 can itself shift cycles.

For most of the peptides here there is no known interaction with hormonal contraception. The exception is tirzepatide: the labeling for the approved products advises a non-oral or backup method for four weeks after starting and after each dose increase, because the drug slows stomach emptying and can reduce absorption of oral contraceptives. Tell the provider what you use, including the route.

The peptides are the same; the goals and the screen differ. Women in their 20s and 30s most often ask about recovery, skin, and desire, and rarely have a reason to use a GH secretagogue while their own output is still high. The pregnancy, breastfeeding, and trying-to-conceive screen-outs matter most in this decade.

GH secretagogues such as sermorelin and CJC-1295/ipamorelin support lean tissue by raising your own GH pulses. The effect is modest, takes months, and only shows up alongside resistance training and adequate protein. They are not anabolic steroids and do not behave like them. Peptide therapy for muscle growth sets realistic expectations.

Generally yes. There is no documented pharmacologic interaction between estrogen, progesterone, or testosterone therapy and the peptides here, and many women use both. Disclose every hormone and its route, because oral estrogen lowers IGF-1 and changes how a GH secretagogue decision is made. Many prescribers settle the HRT dose first and add a peptide afterward.

At PeRx, peptides run from $199 to $349 per prescription, and the compounded GLP-1s are $249 for semaglutide with B12 and $399 for tirzepatide with B12 per 28-day cycle. Everything is cash-pay, though HSA and FSA funds usually apply. There are no auto-renewals outside the two GLP-1 subscriptions, which can be cancelled.

Related Guides

Continue reading about peptides and protocols that pair well with this guide.

Ready to get started?

Pharmaceutical-grade peptides prescribed by a licensed provider, prepared by a US 503A pharmacy, and shipped ready to use.

Medical Disclaimer

The information provided on this website, including all articles, guides, and educational content, is for informational and educational purposes only and is not intended as medical advice, diagnosis, or treatment. Nothing on this site should be construed as a substitute for professional medical advice from a qualified healthcare provider.

The majority of peptides discussed on this site are not approved by the U.S. Food and Drug Administration (FDA) for the indications described. They are classified as bulk drug substances and are available only through a licensed prescribing provider and compounding pharmacy. All treatments require a valid prescription and provider oversight.

The majority of published research on peptide therapies has been conducted in preclinical (animal) models. While early human data is encouraging, comprehensive clinical trial data remains limited for most peptide compounds. Individual results may vary significantly based on health status, injury type, and other factors. No specific outcomes are guaranteed.

Certain peptides discussed on this site are classified as prohibited substances by the World Anti-Doping Agency (WADA) and are banned by major sports organizations including the NFL, NCAA, UFC, NBA, MLB, NHL, and PGA. If you are subject to anti-doping testing, consult your governing body before considering any peptide therapy.

Statements on this website have not been evaluated by the Food and Drug Administration. Products and therapies discussed are not intended to diagnose, treat, cure, or prevent any disease.

© 2026 Wellness MD Group PC DBA PeRx. All rights reserved.